U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Description
Curator's Comment: Description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2003/50168slr078_cotisporin_lbl.pdf

Bacitracin is a polypeptide antibiotic produced by Bacillus subtilis and Bacillus licheniformis. Bacitracin in combination with neomycin and polymyxin B is indicated for the treatment of many bacterial diseases. The antibacterial properties of bacitracin are mediated by its binding to C55-isoprenyl pyrophosphate, resulting in inhibition of cell wall biosynthesis.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
BACITRACIN

Approved Use

Uses first aid to help prevent infection in: •minor cuts •scrapes •burns

Launch Date

1948
Curative
CORTISPORIN

Approved Use

For the treatment of corticosteroid-responsice dermatoses with secondary infection.

Launch Date

1957
Curative
NEOSPORIN

Approved Use

NEOSPORIN Ophthalmic Ointment is indicated for the topical treatment of superficial infections of the external eye and its adnexa caused by susceptible bacteria. Such infections encompass conjunctivitis, keratitis and keratoconjunctivitis, blepharitis and blepharoconjunctivitis.

Launch Date

1968
PubMed

PubMed

TitleDatePubMed
Bacitracin: Methods of Production, Concentration, and Partial Purification, with a Summary of the Chemical Properties of Crude Bacitracin.
1948 Feb
The relative antisyphilitic activity of penicillins F,G,K, and X and of bacitracin, based on the amounts required to abort early syphilic infections in rabbits.
1948 Mar
The Action of Bacitracin and Subtilin on Treponema pallidum in Vitro and in Vivo.
1948 Mar
The Results of the Systemic Administration of the Antibiotic, Bacitracin, in Surgical Infections: A Preliminary Report.
1948 Oct
A Note on the Susceptibility of Hemophilus influenzae Type B to Bacitracin.
1948 Oct
The Use of Bacitracin in Experimental Clostridium Welchii Infection in Guinea Pigs.
1949 Oct
IN VITRO STUDIES ON POSSIBLE SYNERGISTIC ACTION BETWEEN PENICILLIN AND BACITRACIN.
1949 Sep
In vitro sensitivity of Bacillus proteus and Pseudomonas aeruginosa to seven antibiotics; penicillin, streptomycin, bacitracin, polymyxin, aerosporin, aureomycin, and chloromycetin.
1950 Feb
Systemic bacitracin in the treatment of progressive bacterial synergistic gangrene.
1950 Feb
Continuous administration of growth hormone does not prevent the decrease of IGF-I gene expression in zinc-deprived rats despite normalization of liver GH binding.
1998 Dec
Copper transport and its defect in Wilson disease: characterization of the copper-binding domain of Wilson disease ATPase.
2000 Apr
Individual variability in the zinc inducibility of metallothionein-IIA mRNA in human lymphocytes.
2000 Dec 15
Defective antioxidant defense system in patients with a human leptin gene mutation.
2000 Jul
Reduction of oxidative stress and cytokine-induced neutrophil chemoattractant (CINC) expression by red wine polyphenols in zinc deficiency induced intestinal damage of rat.
2000 Jun 1
Therapeutic application of zinc in human immunodeficiency virus against opportunistic infections.
2000 May
Effect of the two conserved prolines of human growth inhibitory factor (metallothionein-3) on its biological activity and structure fluctuation: comparison with a mutant protein.
2000 Nov 28
Dietary zinc deficiency increases uroguanylin accumulation in rat kidney.
2001 Apr
Metallothionein isogene transcription in red blood cell precursors from human cord blood.
2001 Feb
Coexistence of zinc and iron augmented oxidative injuries in the nigrostriatal dopaminergic system of SD rats.
2001 Feb 1
Nitric oxide induces metallothionein (MT) gene expression apparently by displacing zinc bound to MT.
2001 Feb 28
Arsenite-inducible RNA-associated protein (AIRAP) protects cells from arsenite toxicity.
2001 Jan
Tyrphostin [correction of Tryphostin] AG879, a tyrosine kinase inhibitor: prevention of transcriptional activation of the electrophile and the aromatic hydrocarbon response elements.
2001 Jan 15
The human ZIP1 transporter mediates zinc uptake in human K562 erythroleukemia cells.
2001 Jun 22
Cleavage of SNAP-25 by botulinum toxin type A requires receptor-mediated endocytosis, pH-dependent translocation, and zinc.
2001 Mar
p38 activation is required upstream of potassium current enhancement and caspase cleavage in thiol oxidant-induced neuronal apoptosis.
2001 May 15
Loss of vesicular zinc and appearance of perikaryal zinc after seizures induced by pilocarpine.
2001 May 25
Oxidative impairment in scrapie-infected mice is associated with brain metals perturbations and altered antioxidant activities.
2001 Nov
Influence of dietary zinc deficiency during development on hepatic CYP2C11, CYP2C12, CYP3A2, CYP3A9, and CYP3A18 expression in postpubertal male rats.
2001 Nov 1
Zinc deficiency reduces leptin gene expression and leptin secretion in rat adipocytes.
2001 Oct
Metallothionein is required for zinc-induced expression of the macrophage colony stimulating factor gene.
2002
Src-dependent phosphorylation of the epidermal growth factor receptor on tyrosine 845 is required for zinc-induced Ras activation.
2002 Jul 5
Partitioning of accumulated trace metals in the talitrid amphipod crustacean Orchestia gammarellus: a cautionary tale on the use of metallothionein-like proteins as biomarkers.
2002 Jun
Co-assembly of GABA rho subunits with the GABA(A) receptor gamma(2) subunit cloned from white perch retina.
2002 Jun 30
Zinc enhances the expression of interleukin-2 and interleukin-2 receptors in HUT-78 cells by way of NF-kappaB activation.
2002 Oct
Metalloenzyme-like activity of Alzheimer's disease beta-amyloid. Cu-dependent catalytic conversion of dopamine, cholesterol, and biological reducing agents to neurotoxic H(2)O(2).
2002 Oct 25
Evidence for non-isostructural replacement of Zn(2+) with Cd(2+) in the beta-domain of brain-specific metallothionein-3.
2002 Sep 11
Induction of metallothionein by zinc protects from daunorubicin toxicity in rats.
2002 Sep 30
Interrelationships among brain, endocrine and immune response in ageing and successful ageing: role of metallothionein III isoform.
2003 Apr
Effect of chromium on apolipoprotein A-I expression in HepG2 cells.
2003 Apr
Changes in rat hepatic gene expression in response to zinc deficiency as assessed by DNA arrays.
2003 Apr
The acrodermatitis enteropathica gene ZIP4 encodes a tissue-specific, zinc-regulated zinc transporter in mice.
2003 Aug 29
Human peptidoglycan recognition protein-L is an N-acetylmuramoyl-L-alanine amidase.
2003 Dec 5
Chromium(VI) down-regulates heavy metal-induced metallothionein gene transcription by modifying transactivation potential of the key transcription factor, metal-responsive transcription factor 1.
2003 Jul 11
In vitro effect of metal ions on the activity of two amphibian glyceraldehyde-3-phosphate dehydrogenases: potential metal binding sites.
2003 Jun
Zinc accumulation in N-methyl-N-nitrosourea-induced rat mammary tumors is accompanied by an altered expression of ZnT-1 and metallothionein.
2003 Jun
Interaction of Tl+ with product complexes of fructose-1,6-bisphosphatase.
2003 May 2
Zinc modulates PPARgamma signaling and activation of porcine endothelial cells.
2003 Oct
Prion, amyloid beta-derived Cu(II) ions, or free Zn(II) ions support S-nitroso-dependent autocleavage of glypican-1 heparan sulfate.
2003 Oct 3
Thymulin evokes IL-6-C/EBPbeta regenerative repair and TNF-alpha silencing during endotoxin exposure in fetal lung explants.
2004 Mar
Bacitracin Inhibits the Migration of U87-MG Glioma Cells via Interferences of the Integrin Outside-in Signaling Pathway.
2016 Mar
Patents

Sample Use Guides

In Vivo Use Guide
Curator's Comment: Bacitracin can be used as ophtalmic solution (0.025mg/ml) for the treatment of superficial ocular infections.
400 units, topically
Route of Administration: Topical
The MIC value was 32 mg/L for Staphylococcus aureus wild type strain after 48h incubation at 37°C.
Substance Class Mixture
Created
by admin
on Wed Apr 02 09:38:17 GMT 2025
Edited
by admin
on Wed Apr 02 09:38:17 GMT 2025
Record UNII
58H6RWO52I
Record Status Validated (UNII)
Record Version
  • Download
Related Record Type
Name Type Language
BACI-RX
Preferred Name English
Bacitracin
EP   HSDB   INN   MI   ORANGE BOOK   USP   USP-RS   VANDF   WHO-DD   WHO-IP  
INN  
Official Name English
BACITRACIN [USP IMPURITY]
Common Name English
TOPITRACIN
Common Name English
NSC-755905
Code English
LANABIOTIC COMPONENT BACITRACIN
Common Name English
BACITRACIN [WHO-IP]
Common Name English
PENITRACIN
Common Name English
BACITRACIN [EP MONOGRAPH]
Common Name English
MYCITRACIN COMPONENT BACITRACIN
Common Name English
FORTRACIN
Common Name English
BACITRACIN [JAN]
Common Name English
BACITRACIN [VANDF]
Common Name English
BACIIM
Brand Name English
PARENTRACIN
Common Name English
BACITRACIN [USP MONOGRAPH]
Common Name English
BACIGUENT
Brand Name English
BACITRACIN [ORANGE BOOK]
Common Name English
BACILLIQUIN
Common Name English
Bacitracin [WHO-DD]
Common Name English
BACITRACIN [HSDB]
Common Name English
BACITRACINUM [WHO-IP LATIN]
Common Name English
ZUTRACIN
Common Name English
TROPITRACIN
Common Name English
bacitracin [INN]
Common Name English
BACITRACIN(NON-INJECTABLE) [WHO-IP]
Common Name English
BACITRACIN [MI]
Common Name English
Classification Tree Code System Code
FDA ORPHAN DRUG 1284
Created by admin on Wed Apr 02 09:38:17 GMT 2025 , Edited by admin on Wed Apr 02 09:38:17 GMT 2025
WHO-VATC QR02AB04
Created by admin on Wed Apr 02 09:38:17 GMT 2025 , Edited by admin on Wed Apr 02 09:38:17 GMT 2025
WHO-ATC J01XX10
Created by admin on Wed Apr 02 09:38:17 GMT 2025 , Edited by admin on Wed Apr 02 09:38:17 GMT 2025
CFR 21 CFR 333.120
Created by admin on Wed Apr 02 09:38:17 GMT 2025 , Edited by admin on Wed Apr 02 09:38:17 GMT 2025
CFR 21 CFR 524.155
Created by admin on Wed Apr 02 09:38:17 GMT 2025 , Edited by admin on Wed Apr 02 09:38:17 GMT 2025
WHO-ATC R02AB04
Created by admin on Wed Apr 02 09:38:17 GMT 2025 , Edited by admin on Wed Apr 02 09:38:17 GMT 2025
CFR 21 CFR 556.70
Created by admin on Wed Apr 02 09:38:17 GMT 2025 , Edited by admin on Wed Apr 02 09:38:17 GMT 2025
EPA PESTICIDE CODE 6302
Created by admin on Wed Apr 02 09:38:17 GMT 2025 , Edited by admin on Wed Apr 02 09:38:17 GMT 2025
CFR 21 CFR 333.110
Created by admin on Wed Apr 02 09:38:17 GMT 2025 , Edited by admin on Wed Apr 02 09:38:17 GMT 2025
CFR 21 CFR 524.154
Created by admin on Wed Apr 02 09:38:17 GMT 2025 , Edited by admin on Wed Apr 02 09:38:17 GMT 2025
CFR 21 CFR 520.154
Created by admin on Wed Apr 02 09:38:17 GMT 2025 , Edited by admin on Wed Apr 02 09:38:17 GMT 2025
WHO-ATC D06AX05
Created by admin on Wed Apr 02 09:38:17 GMT 2025 , Edited by admin on Wed Apr 02 09:38:17 GMT 2025
WHO-VATC QJ01XX10
Created by admin on Wed Apr 02 09:38:17 GMT 2025 , Edited by admin on Wed Apr 02 09:38:17 GMT 2025
WHO-VATC QD06AX05
Created by admin on Wed Apr 02 09:38:17 GMT 2025 , Edited by admin on Wed Apr 02 09:38:17 GMT 2025
WHO-VATC QA07AA93
Created by admin on Wed Apr 02 09:38:17 GMT 2025 , Edited by admin on Wed Apr 02 09:38:17 GMT 2025
Code System Code Type Description
WIKIPEDIA
BACITRACIN
Created by admin on Wed Apr 02 09:38:17 GMT 2025 , Edited by admin on Wed Apr 02 09:38:17 GMT 2025
PRIMARY
SMS_ID
100000092135
Created by admin on Wed Apr 02 09:38:17 GMT 2025 , Edited by admin on Wed Apr 02 09:38:17 GMT 2025
PRIMARY
ECHA (EC/EINECS)
215-786-2
Created by admin on Wed Apr 02 09:38:17 GMT 2025 , Edited by admin on Wed Apr 02 09:38:17 GMT 2025
PRIMARY
NSC
755905
Created by admin on Wed Apr 02 09:38:17 GMT 2025 , Edited by admin on Wed Apr 02 09:38:17 GMT 2025
PRIMARY
EVMPD
SUB00652MIG
Created by admin on Wed Apr 02 09:38:17 GMT 2025 , Edited by admin on Wed Apr 02 09:38:17 GMT 2025
PRIMARY
RXCUI
1291
Created by admin on Wed Apr 02 09:38:17 GMT 2025 , Edited by admin on Wed Apr 02 09:38:17 GMT 2025
PRIMARY RxNorm
WHO INTERNATIONAL PHARMACOPEIA
BACITRACIN
Created by admin on Wed Apr 02 09:38:17 GMT 2025 , Edited by admin on Wed Apr 02 09:38:17 GMT 2025
PRIMARY Description: A white or pale brownish yellow powder; odourless or with a faint characteristic odour. Solubility: Freely soluble in water, methanol R and ethanol (~750 g/l) TS; practically insoluble in acetone R and ether R. Category: Antiinfective drug. Storage: Bacitracin should be kept in a tightly closed container, protected from light and stored at a temperature between 2? and8?C. If it is intended for parenteral administration, the container should be sterile and sealed so as to exclude micro-organisms. Labelling: The designation sterile Bacitracin indicates that the substance complies with the additional requirements for sterileBacitracin and may be used for parenteral administration or for other sterile applications. Additional information: Bacitracin is hygroscopic. Its solutions deteriorate rapidly at room temperature. Even in the absence oflight, it is gradually degraded on exposure to a humid atmosphere, the decomposition being faster at higher temperatures.
DRUG BANK
DB00626
Created by admin on Wed Apr 02 09:38:17 GMT 2025 , Edited by admin on Wed Apr 02 09:38:17 GMT 2025
PRIMARY
FDA UNII
58H6RWO52I
Created by admin on Wed Apr 02 09:38:17 GMT 2025 , Edited by admin on Wed Apr 02 09:38:17 GMT 2025
PRIMARY
NCI_THESAURUS
C295
Created by admin on Wed Apr 02 09:38:17 GMT 2025 , Edited by admin on Wed Apr 02 09:38:17 GMT 2025
PRIMARY
INN
1167
Created by admin on Wed Apr 02 09:38:17 GMT 2025 , Edited by admin on Wed Apr 02 09:38:17 GMT 2025
PRIMARY
MERCK INDEX
m2197
Created by admin on Wed Apr 02 09:38:17 GMT 2025 , Edited by admin on Wed Apr 02 09:38:17 GMT 2025
PRIMARY Merck Index
NDF-RT
N0000008479
Created by admin on Wed Apr 02 09:38:17 GMT 2025 , Edited by admin on Wed Apr 02 09:38:17 GMT 2025
PRIMARY Decreased Cell Wall Synthesis & Repair [PE]
LACTMED
Bacitracin
Created by admin on Wed Apr 02 09:38:17 GMT 2025 , Edited by admin on Wed Apr 02 09:38:17 GMT 2025
PRIMARY
DAILYMED
58H6RWO52I
Created by admin on Wed Apr 02 09:38:17 GMT 2025 , Edited by admin on Wed Apr 02 09:38:17 GMT 2025
PRIMARY
MESH
D001414
Created by admin on Wed Apr 02 09:38:17 GMT 2025 , Edited by admin on Wed Apr 02 09:38:17 GMT 2025
PRIMARY
CAS
1405-87-4
Created by admin on Wed Apr 02 09:38:17 GMT 2025 , Edited by admin on Wed Apr 02 09:38:17 GMT 2025
PRIMARY
ChEMBL
CHEMBL1200558
Created by admin on Wed Apr 02 09:38:17 GMT 2025 , Edited by admin on Wed Apr 02 09:38:17 GMT 2025
PRIMARY
DRUG CENTRAL
281
Created by admin on Wed Apr 02 09:38:17 GMT 2025 , Edited by admin on Wed Apr 02 09:38:17 GMT 2025
PRIMARY
CHEBI
28669
Created by admin on Wed Apr 02 09:38:17 GMT 2025 , Edited by admin on Wed Apr 02 09:38:17 GMT 2025
PRIMARY
Related Record Type Details
TARGET -> INHIBITOR
MIC
TARGET -> INHIBITOR
SALT/SOLVATE -> PARENT
SUB_CONCEPT->SUBSTANCE
Related Record Type Details
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
sum of impurities L and N: maximum 8.0 per cent
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
sum of impurities L and N: maximum 8.0 per cent
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
sum of impurities F and G: maximum 2.0 per cent
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
sum of impurities O, P and Q: maximum 2.5 per cent
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
sum of impurities F and G: maximum 2.0 per cent
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
sum of impurities O, P and Q: maximum 2.5 per cent
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
sum of impurities O, P and Q: maximum 2.5 per cent
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
ACTIVE MOIETY
http://apps.who.int/phint/pdf/b/Jb.6.1.40.pdf
Definition References